About: Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
Creator	Irsch, Johannes Lanteri, Marion Stassinopoulos, Adonis Bringmann, Peter Girard, Yvette Laughhunn, Andrew Payrat, Jean-Marc Picard-Maureau, Marcus Santa-Maria, Felicia
Source	Medline; PMC
abstract	BACKGROUND: The INTERCEPT Blood System pathogen reduction technology (PRT), which uses amotosalen and ultraviolet A light treatment (amotosalen/UV‐PRT), inactivates pathogens in plasma and platelet components (PCs). This review summarizes data describing the inactivation efficacy of amotosalen/UVA‐PRT for a broad spectrum of viruses and parasites. METHODS: Twenty‐five enveloped viruses, six nonenveloped viruses (NEVs), and four parasites species were evaluated for sensitivity to amotosalen/UVA‐PRT. Pathogens were spiked into plasma and PC at high titers. Samples were collected before and after PRT and assessed for infectivity with cell cultures or animal models. Log reduction factors (LRFs) were defined as the difference in infectious titers before and after amotosalen/UV‐PRT. RESULTS: LRFs of ≥4.0 log were reported for 19 pathogens in plasma (range, ≥4.0 to ≥7.6), 28 pathogens in PC in platelet additive solution (PC‐PAS; ≥4.1‐≥7.8), and 14 pathogens in PC in 100% plasma (PC‐100%; (≥4.3‐>8.4). Twenty‐five enveloped viruses and two NEVs were sensitive to amotosalen/UV‐PRT; LRF ranged from >2.9 to ≥7.6 in plasma, 2.4 or greater to greater than 6.9 in PC‐PAS and >3.5 to >6.5 in PC‐100%. Infectious titers for four parasites were reduced by >4.0 log in all PC and plasma (≥4.9 to >8.4). CONCLUSION: Amotosalen/UVA‐PRT demonstrated effective infectious titer reduction for a broad spectrum of viruses and parasites. This confirms the capacity of this system to reduce the risk of viral and parasitic transfusion‐transmitted infections by plasma and PCs in various geographies.
has issue date	2020-04-24(xsd:dateTime)
bibo:doi	10.1111/trf.15807
bibo:pmid	32333396
has license	cc-by-nc-nd
sha1sum (hex)	4ba9df1b49ea8870a59e7027ddb701569b5dd94c
schema:url	https://doi.org/10.1111/trf.15807
resource representing a document's title	Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
has PubMed Central identifier	PMC7317863
has PubMed identifier	32333396
schema:publication	Transfusion
resource representing a document's body	covid:4ba9df1b49ea8870a59e7027ddb701569b5dd94c#body_text
is schema:about of	named entity 'light' named entity 'parasites' named entity 'plasma' named entity 'medical treatments' named entity 'genome' named entity 'UVA light' named entity 'parasites' named entity 'Jish' named entity 'United States' named entity 'pathogen' named entity 'HBV' named entity 'P. falciparum' named entity 'Europe' named entity 'blood components' named entity 'WNV' named entity 'Virus' named entity 'vaccine' named entity 'transfusion' named entity 'parasites' named entity 'blood component' named entity 'clinical symptoms' named entity 'organism' named entity 'UVA' named entity 'cytopathic effect' named entity 'platelets' named entity 'sexual behavior' named entity 'Canada' named entity 'plasma' named entity 'animal models' named entity 'Virologic' named entity 'nucleic acids' named entity 'plasma' named entity 'globalization' named entity 'Babesia' named entity 'risk exposure' named entity 'endemic' named entity 'transfusion' named entity 'men who have sex with men' named entity 'inoculation' named entity 'parasitemia' named entity 'endemic areas' named entity 'pathogen' named entity 'CE mark' named entity 'Mayaro virus' named entity 'Chagas disease' named entity 'COVID-19' named entity 'high-risk' named entity 'UVA' named entity 'plasma' named entity 'dengue virus' named entity 'reoviruses' named entity 'ATCC' named entity 'plasma' named entity 'antiretroviral drugs' named entity 'infectious diseases' named entity 'blood products' named entity 'RBC' named entity 'antigen' named entity 'SARS-CoV-2' named entity 'mortality rates' named entity 'incubation' named entity 'United States' named entity 'cell lines' named entity 'yellow fever virus' named entity 'hepatitis B virus' named entity 'prophylaxis' named entity 'Europe' named entity 'WNV' named entity '2017-2018' named entity 'parvovirus B19' named entity 'pathogen' named entity 'HEV' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software